CCL19 as a Biomarker May Track IgG4-Related Disease Activity

Published Date: 11 Jun 2026

CCL19 emerges as a promising biomarker that distinguishes active disease from treatment-induced remission and may help to identify relapsing disease in patients with IgG4-related disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

2.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

3.

Millions of men could benefit from faster scan to diagnose prostate cancer

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot